Toward tuberculosis vaccine development: Recommendations for nonhuman primate study design

Dominick J. Laddy; Aurelio Bonavia; Willem A. Hanekom; Deepak Kaushal; Ann Williams; Mario Roederer; Robert A. Seder; Sally Sharpe; Frank A.W. Verreck; Patricia A. Darrah

doi:10.1128/IAI.00776-17

Toward tuberculosis vaccine development: Recommendations for nonhuman primate study design

Dominick J. Laddy
, Aurelio Bonavia
, Willem A. Hanekom
, Deepak Kaushal
, Ann Williams
, Mario Roederer
, Robert A. Seder
, Sally Sharpe
, Frank A.W. Verreck
, Patricia A. Darrah^*

^*Corresponding author for this work

Countermeasures Development & Evaluation Scientific Leaders

Research output: Contribution to journal › Article › peer-review

26 Citations (Scopus)

Abstract

Clinical trials of novel tuberculosis (TB) vaccines are expensive, while global resources for TB vaccine development are limited. Therefore, there is a need for robust and predictive preclinical data to support advancement of candidate vaccines into clinical trials. Here, we provide a rationale for using the nonhuman primate as an essential component of these efforts, as well as guidance to the TB community for standardizing experimental design and aligning endpoints to facilitate development of new TB vaccines.

Original language	English
Article number	e00776-17
Journal	Infection and Immunity
Volume	86
Issue number	2
DOIs	https://doi.org/10.1128/IAI.00776-17
Publication status	Published - 1 Feb 2018

Bibliographical note

Publisher Copyright:
© 2018 American Society for Microbiology.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Nonhuman primate
Tuberculosis
Vaccines

Access to Document

10.1128/IAI.00776-17

Cite this

@article{43de0e2892214f618e4075fbe08fbba7,

title = "Toward tuberculosis vaccine development: Recommendations for nonhuman primate study design",

abstract = "Clinical trials of novel tuberculosis (TB) vaccines are expensive, while global resources for TB vaccine development are limited. Therefore, there is a need for robust and predictive preclinical data to support advancement of candidate vaccines into clinical trials. Here, we provide a rationale for using the nonhuman primate as an essential component of these efforts, as well as guidance to the TB community for standardizing experimental design and aligning endpoints to facilitate development of new TB vaccines.",

keywords = "Nonhuman primate, Tuberculosis, Vaccines",

author = "Laddy, \{Dominick J.\} and Aurelio Bonavia and Hanekom, \{Willem A.\} and Deepak Kaushal and Ann Williams and Mario Roederer and Seder, \{Robert A.\} and Sally Sharpe and Verreck, \{Frank A.W.\} and Darrah, \{Patricia A.\}",

note = "Publisher Copyright: {\textcopyright} 2018 American Society for Microbiology.",

year = "2018",

month = feb,

day = "1",

doi = "10.1128/IAI.00776-17",

language = "English",

volume = "86",

journal = "Infection and Immunity",

issn = "0019-9567",

publisher = "American Society for Microbiology",

number = "2",

}

TY - JOUR

T1 - Toward tuberculosis vaccine development

T2 - Recommendations for nonhuman primate study design

AU - Laddy, Dominick J.

AU - Bonavia, Aurelio

AU - Hanekom, Willem A.

AU - Kaushal, Deepak

AU - Williams, Ann

AU - Roederer, Mario

AU - Seder, Robert A.

AU - Sharpe, Sally

AU - Verreck, Frank A.W.

AU - Darrah, Patricia A.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Clinical trials of novel tuberculosis (TB) vaccines are expensive, while global resources for TB vaccine development are limited. Therefore, there is a need for robust and predictive preclinical data to support advancement of candidate vaccines into clinical trials. Here, we provide a rationale for using the nonhuman primate as an essential component of these efforts, as well as guidance to the TB community for standardizing experimental design and aligning endpoints to facilitate development of new TB vaccines.

AB - Clinical trials of novel tuberculosis (TB) vaccines are expensive, while global resources for TB vaccine development are limited. Therefore, there is a need for robust and predictive preclinical data to support advancement of candidate vaccines into clinical trials. Here, we provide a rationale for using the nonhuman primate as an essential component of these efforts, as well as guidance to the TB community for standardizing experimental design and aligning endpoints to facilitate development of new TB vaccines.

KW - Nonhuman primate

KW - Tuberculosis

KW - Vaccines

UR - https://www.scopus.com/pages/publications/85041009162

U2 - 10.1128/IAI.00776-17

DO - 10.1128/IAI.00776-17

M3 - Article

C2 - 29203540

AN - SCOPUS:85041009162

SN - 0019-9567

VL - 86

JO - Infection and Immunity

JF - Infection and Immunity

IS - 2

M1 - e00776-17

ER -

Toward tuberculosis vaccine development: Recommendations for nonhuman primate study design

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this